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Metallothionein (MT) crypt-restricted immunopositivity indices (MTCRII) are colonic crypt stem cell mutation markers that may be
induced early and in abundance after mutagen treatment. Metallothionein is the endogenous reporter gene for MTCRII, but is not
typically implicated in the classical pathway of colorectal tumorigenesis. Hence, the oncological relevance of MTCRII is unclear. This
study tests the hypothesis that MTCRII induced by N-methyl-N-nitrosourea (MNU) and lambda carrageenan (lCgN) associate with
aberrant crypt foci (ACF) in mouse colon. Undegraded lCgN and MNU were tested alone and in combination against MTCRII and
ACF in Balb/c mice, at 20 weeks after the start of treatment. MTCRII were unaffected by lCgN alone. Combined lCgN/MNU
treatments induced greater MTCRII (Po0.01) as well as greater number (Po0.001) and crypt multiplicity (Po0.01) of ACF than
MNU alone. MTCRII were approximately 10-fold more numerous than ACF, although linear correlations were observed between
these parameters (r¼ 0.732; Po0.01). MTCRII are induced by lCgN/MNU interactions in sufficient numbers to provide statistical
power from relatively small sample sizes and correlate with ACF formation. MTCRII could thus provide the basis for a novel medium-
term murine bioassay relevant to early-stage colorectal tumorigenesis.
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Humans are exposed to mixtures of genotoxic and nongenotoxic
environmental chemicals that may be linked to cancer (Burkart
and Jung, 1998; Minamoto et al, 1999). Robust biomarkers of
somatic stem cell mutation and mutant clonal expansion may
provide cancer surrogates that are useful for risk assessment.
Acquired mutation of a selectable endogenous reporter gene like
glucose-6-phosphate dehydrogenase (G6PD) within a colonic crypt
stem cell induces a crypt-restricted phenotype change (Griffiths
et al, 1988; Park et al, 1995; Kuraguchi et al, 1997). Stable, crypt-
restricted immunopositivity for metallothionein (MT) is a more
recently described stem cell mutation marker for mouse colon
that can be assayed in paraffin-fixed tissue sections and has
been validated against the G6PD assay (Cook et al, 2000).
MT-immunopositive crypt frequency has shown a dose response
to three different chemical mutagens (Jasani et al, 1998; Cook et al,
2000; Donnelly et al, 2004), which strengthens the evidence that it
is a somatic mutation marker.
We have previously shown that a model genotoxic/nongenotoxic
chemical mixture, comprising N-methyl-N-nitrosourea (MNU) and
undegraded lambda carrageenan (lCgN), have interactive effects
upon MT crypt-restricted immunopositivity indices (MTCRII),
including frequency and size of MT-immunopositive foci and total
number of MT-immunopositive crypts (Donnelly et al, 2004).
However, the role of MT mutation in the classical molecular
pathway of colorectal cancer is uncertain and thus the oncological
relevance of MTCRII is unclear.
This study assesses MTCRII induced by similar MNU/lCgN
regimens as in our previous investigation (Donnelly et al, 2004)
against aberrant crypt foci (ACF) in mouse colon. MTCRII develop
within 4–6 weeks of mutagen exposure (Jasani et al, 1998; Cook
et al, 2000). ACF represent the earliest morphological stage of
colorectal tumorigenesis (McLellan et al, 1991). Some early ACF
may regress (Shpitz et al, 1996), although large ACF that develop
at late intervals after mutagen treatment may have greater risk
of dysplasia and cancer (Papanikolaou et al, 2000). In this study
therefore, assays were conducted at 20 weeks after mutagen
treatment to enable assessment of MTCRII against large or
persistent ACF.
MATERIALS AND METHODS
Chemicals, reagents, animals and treatment regimens were as
described previously (Donnelly et al, 2004). Anti-MT primary
antibody (mouse anti-horse monoclonal E9, isotype : IgG1)
and peroxidase-conjugated rabbit anti-mouse immunoglobulins
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were obtained from DAKO Ltd, Ely, Cambridgeshire, UK
(Dako M0639 and P0161 respectively), as described pre-
viously (Jasani et al, 1998; Cook et al, 2000). Methylene blue was
obtained from BDH Chemicals Ltd, Poole, Dorset, UK (BDH
34048).
Animals and treatment regimes
Female adult Balb/c mice, aged 6– 8 weeks, were obtained from
Harlan UK Ltd, Bicester, Oxon, UK, divided into groups of five
or 10, ear-punched and placed in coded stainless-steel wire cages,
maintained and fed as outlined previously (Donnelly et al, 2004).
Individual animal weights and group fluid and AIN-76 diet
consumption were assessed daily, during weekdays.
Treatment groups
In all, 90 female adult Balb/c mice aged 6–8 weeks were divided
into 11 groups of five or 10 that received no MNU, MNU
(62.5 mg kg1 dissolved in dimethylsulphoxide (DMSO)) alone or
in combination with 1 or 4% lCgN as follows:
Group 1 (n¼ 5): Drinking water only for 20 weeks (water only
control).
Group 2 (n¼ 5): Single intraperitoneal (i.p.) injection of vehicle
(DMSO), then drinking water for 20 weeks
(vehicle control).
Group 3 (n¼ 5): Continuous 1% lCgN only for 20 weeks.
Group 4 (n¼ 5): Continuous 4% lCgN only for 20 weeks.
Group 5 (n¼ 10): MNU 62.5 mg kg1 i.p., then drinking water
only for 20 weeks.
Group 6 (n¼ 10): MNU 62.5 mg kg1 i.p. and 1% lCgN for 7 days
during week 1, then drinking water until 20
weeks.
Group 7 (n¼ 10): MNU 62.5 mg kg1 i.p. and 4% lCgN for 7 days
during week 1, then drinking water until 20
weeks.
Group 8 (n¼ 10): MNU 62.5 mg kg1 i.p. and three 7-day treat-
ments of 1% lCgN during weeks 1, 4 and 7.
Drinking water was given between and after
lCgN treatments until 20 weeks.
Group 9 (n¼ 10): MNU 62.5 mg kg1 i.p. and three 7-day treat-
ments of 4% lCgN during weeks 1, 4 and 7.
Drinking water was given between and after
lCgN treatments until 20 weeks.
Group 10 (n¼ 10): MNU 62.5 mg kg1 i.p. and continuous 1%
lCgN treatment until 20 weeks.
Group 11 (n¼ 10): MNU 62.5 mg kg1 i.p. and continuous 4%
lCgN treatment until 20 weeks.
In combined regimens, MNU was administered after the first 5
days of lCgN treatment.
Welfare considerations and weight index
Animal welfare considerations were strictly in accordance
with OECD guidelines (OECD, 2002). Animals were weighed
daily and weight index was calculated as the ratio at study
completion relative to weight at study start. Values for mean
weight index were compared between treatment groups, at study
completion.
Assay of ACF
All assays of ACF were blinded to treatment and carried out after
colonic retrieval at 20 weeks after the initiation of treatment.
Colons were carefully pinned flat on a cork mat, painted with 0.1%
methylene blue and left at room temperature for 10 min. Assay of
ACF was performed using a dissecting microscope at  40
magnification and the following parameters were recorded:
(i) ACF number: Assessed as the total number of ACF per colon
or per 104 colonic crypts.
(ii) ACF size (crypt multiplicity): Crypt multiplicity was deter-
mined as the number of aberrant crypts per ACF.
Colons were then ‘Swiss-rolled’ on the cork mat, with the
ileocaecal junction at the centre of the roll, fixed in neutral formal
saline for 48 h, and embedded in paraffin wax blocks.
Assay of MTCRII
All assays of MTCRII were blinded to treatment and carried out
20 weeks after the initiation of treatment. MTCRII were assayed
as described previously (Donnelly et al, 2004). Briefly, paraffin-
embedded sections (4mm thickness) were cut at 10 levels (L1–
L10), 100 mm apart through the ‘Swiss-rolled’ colon. One section
from each level was stained using a standard indirect immunoper-
oxidase technique for MT, while endogenous peroxidase activity
was blocked using 3% hydrogen peroxide in methanol. Slides were
incubated with an anti-MT primary antibody (E9, isotype : IgG1;
100ml per slide) (DAKO Ltd, Ely, Cambridgeshire, UK). The
secondary antibody used was horseradish peroxidase-conjugated
rabbit anti-mouse immunoglobulin (Dako catalogue no. P0161).
Negative control sections were incubated either in the absence
of antibody, in normal mouse serum (1 : 1000), or with an irre-
levant antibody of the same IgG subclass (1 : 1000) (IgG1; Dako
catalogue product code X0931). These were consistently negative.
Positive control sections included mouse colon previously treated
by N-ethyl-N-nitrosourea (ENU; 250 mg kg1), which induces MT-
immunopositive crypts (Cook et al, 2000). Sections were washed
and 100 ml of the chromogen 3,30-diaminobenzidine tetrahydro-
chloride was added before counter-staining with Harris haema-
toxylin. The frequency and size of MT-immunopositive foci as well
as total number of MT-immunopositive crypts were assessed
as follows:
(i) MT-immunopositive single crypts or patches of X2 conti-
guous MT-immunopositive crypts were recognised by their
dark brown stain against a haematoxylin background and
were assessed in transverse or longitudinal section through
the crypt lumen. Each single or contiguous patch of X2 MT-
immunopositive crypts was considered to represent a single
mutant focus.
(ii) The size of each MT-immunopositive patch was assessed by
the number of contiguous MT-immunopositive crypts within
the patch. Patches were recorded as doubles, triples or greater
(n¼ 2, 3, etc., MT-immunopositive crypts).
(iii) The total number of MT-immunopositive crypts per mouse
colon was determined by the sum of single immunopositives
and all immunopositives within patches.
Endpoints of the (i) frequency of MT-immunopositive foci (ii)
number of MT-immunopositive patches and (iii) the total number
of MT-immunopositive crypts were expressed as the number per
104 total crypts, in mouse colon.
Data analysis
Serial weight data were available in individual mice. The weight
index was calculated as the weight at study completion relative to
weight at study start, expressed as a percentage. Between-group
differences of weight index were assessed by one-way ANOVA.
Descriptive statistics applied to weight index were expressed as
mean7standard deviation (mean7s.d.). Group data were avail-
able for consumption of food and fluid, which were assessed in
grams or ml per kg body weight, respectively. Descriptive statistics
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were expressed as mean7s.d. To achieve a normal distribution,
MTCRII and ACF data from each treatment group were
log transformed to ensure a normal distribution and assessed
by a probability plot of residuals. Transformed data were analysed
by univariate ANOVA. Duncan post hoc tests were applied
to assess differences between specific treatment regimens.
Differences of MT-immunopositive patch formation between
MNU alone and all combinations of lCgN/MNU were assessed
by Student’s t-test. Correlations between MTCRII and ACF data
were investigated by Pearson’s product moment coefficient. SPSS
for Windows (version 11) was used for statistical analysis (SPSS
Inc., Chicago, Il, USA).
RESULTS
Food, fluid intake and body weight
In all, 11 treatment groups of mice (n¼ 90 total) received water-
or vehicle-only controls, high- or low-dose lCgN alone or in
combination with MNU (62.5 mg kg1 i.p.). lCgN was given in
single or recurrent short- or long-term patterns of exposure.
Group values for fluid, food intake and weight index are shown in
Table 1. No significant between-group differences of weight index
were observed at study completion (Table 1).
Treatment effects upon MTCRII
Group values for MTCRII, including total number of MT-
immunopositive crypts, MT-immunopositive patch formation
and frequency of MT-immunopositive foci, are shown in Table 2.
The total number of MT-immunopositive crypts was increased by
425-fold in excess of that of vehicle alone, by MNU (62.5 mg kg1)
treatment, but was unaffected by lCgN treatment alone. Data
analysis by one-way between-group ANOVA with the Duncan post
hoc test allowed division of results into statistically different
subsets. Combined lCgN/MNU regimens induced significantly
greater total number of MT-immunopositive crypts compared to
MNU alone or treatments lacking MNU (Po0.01; Table 2).
Significant incremental differences were observed between treat-
ment subsets (A– C), where A represents treatment groups 1 –4, B
represents groups 5 and 6 and C represents groups 8 and 11.
Treatment groups 7, 9 and 10 overlapped subsets B and C
(Figure 1A).
Significant between-group differences in the frequency of
patches of X2 contiguous MT-immunopositive crypts were also
observed (Po0.05; ANOVA). Significant incremental differences
were observed between three treatment subsets (A–C), where A
represents treatment groups 1– 4, B represents group 5 and C
represents groups 7 and 9. Treatment groups 6, 8, 10 and 11
overlapped subsets B and C (Figure 1B). Over 95% of mutant
patches involved only two contiguous mutant crypts. The
frequency of large MT-immunopositive patches (X3 contiguous
immunopositive crypts) was 0.3870.5 per 104 total crypts for
MNU alone (group 5) vs 1.1271.01 per 104 total crypts for all
MNU/lCgN treatment groups (P¼ 0.002). All patches of X4 MT-
immunopositive crypts were observed in combined lCgN/MNU
treatment groups.
Effect of treatment regimes on ACF frequency
The administration of MNU led to a significant increase in ACF
numbers by about 10-fold in excess of that of DMSO vehicle alone.
ACF data were expressed either as a number per 104 total colonic
crypts (Figure 2A) or per mouse colon (Table 3). lCgN treatment
alone led to a small significant increase in ACF size, in terms of
crypt multiplicity but had no significant effect on ACF number.
Combined lCgN/MNU regimens significantly increased ACF
number and size (Po0.001; ANOVA). Post hoc analysis demon-
strated significant incremental differences in ACF number between
five homogeneous treatment subsets (A–E), where A represents
treatment groups 1–4, B represents treatment group 5, C
represents groups 6 and 7, D represents group 8 and E represents
groups 9 and 11. Group 10 overlapped subsets C and D (Figure 2A;
Table 3). Significant effects of treatment on ACF size were also
observed (Po0.01; Figure 2B) with incremental differences in
Table 1 Effects of 20-week treatments on group fluid and food
consumption and weight index
Treatment regimes Mice (n)
Group
fluid
intake
(ml g1
body
weight)
Group
food
intake
(g g1
body
weight)
Weight
index
1. Control (water) only 5 0.165 0.184 132.7272.2
2. DMSO vehicle only 5 0.163 0.192 133.7172.5
3. Continuous 1% lCgN 5 0.172 0.174 126.5173.4
4. Continuous 4% lCgN 5 0.113 0.184 132.0974.7
5. MNU (62.5 mg kg1) 10 0.152 0.161 126.5876.5
6. MNU+1 7 day 1% lCgN 10 0.151 0.170 130.4976.9
7. MNU+1 7 day 4% lCgN 10 0.149 0.165 126.4375.4
8. MNU+3 7 day 1% lCgN 10 0.149 0.167 133.2976.9
9. MNU+3 7 day 4% lCgN 10 0.122 0.165 129.9573.9
10. MNU+continuous 1% lCgN 10 0.137 0.164 130.2274.6
11. MNU+continuous 4% lCgN 10 0.114 0.165 125.4176.2
DMSO¼ dimethylsulphoxide; lCgN¼ lambda carrageenan; MNU¼N-methyl-N-
nitrosourea.
Table 2 Treatment effects upon MTCRII
Treatment Mice (n) Total crypt no.
Total MT-immunopositive
crypt number
Patches X2 MT-
immunopositive crypts
Frequency of MT-
immunopositive foci
1. Water only 5 36 43372053 1.13470.34 0.1070.06 1.13070.33
2. DMSO only 5 33 29272888 0.97470.29 0 0.9770.29
3. Continuous 1% lCgN 5 37 02572091 0.8870.32 0 0.8870.33
4. Continuous 4% lCgN 5 38 65771149 1.3170.32 0 1.3170.32
5. MNU only (62.5 mg kg1) 10 29 75071925 37.6672.93 5.5470.91 31.7372.66
6. MNU+1 7-day cycle 1% lCgN 10 27 71571715 46.5475.63 6.7671.10 38.6075.18
7. MNU+1 7-day cycle 4% lCgN 10 32 53971543 52.3174.82 9.6170.78 39.3974.72
8. MNU+3 7-day cycles 1% lCgN 10 30 65172091 59.8576.91 8.2771.56 51.4676.81
9. MNU+3 7-day cycles 4% lCgN 10 30 64073176 52.4777.80 9.6270.67 43.7975.89
10. MNU+continuous 1% lCgN 10 31 37271832 47.8675.96 8.0071.14 38.1475.11
11. MNU+continuous 4% lCgN 10 23 45071007 56.2375.41 5.8270.69 49.9875.09
MTCRII¼metallothionein crypt-restricted immunopositivity indices; MT¼metallothionein; DMSO¼ dimethylsulphoxide; lCgN¼ lambda carrageenan; MNU¼N-methyl-N-
nitrosourea.
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crypt multiplicity within ACF between five treatment subsets
(A– E), where A represents treatment groups 1 and 2, B represents
3 and 4, C represents group 5 and 6, D groups 9 and 11 and E
represents group 8. Groups 7 and 10 overlapped subsets D and E.
Correlations between MTCRII and ACF
Assessments of MTCRII and ACF were conducted in all treatment
groups (1–11). Linear correlations were observed between total
MT-immunopositive crypt number and ACF number per 104
crypts (r¼ 0.732; Po0.01) (Figure 3A) and ACF size, in terms of
the number of aberrant crypts per focus (r¼ 0.84; Po 0.01)
(Figure 3B).
DISCUSSION
Colonic tumorigenesis involves acquisition of mutations or
heritable epigenetic events, affecting growth control or differentia-
tion genes within crypt stem cells, progression to premalignant
stages including ACF (Bird and Good, 2000) and ultimate invasive
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Figure 1 Treatment effects upon MTCRII. (A) Total MT-immuno-
positive crypt number per 104 crypts in each treatment group. Significant
between-group treatment differences were observed (Po0.01). The
Duncan post hoc test identified three distinct homogeneous treatment
subsets (A–C), showing significant incremental differences in total mutation
load: (A) Groups 1–4, distilled water, DMSO or lCgN only (1 and 4%); (B)
Groups 5 and 6, MNU only or MNU and one 7 day cycle of 1% lCgN; (C)
Groups 8 and 11, MNU and three 7 day cycles of 1% lCgN or MNU and
continuous 4% lCgN. Groups 7, 9 and 10 overlapped subsets B and C. (B)
Formation of patches ofX2 contiguous MT immunopositive crypts in each
treatment group. The Duncan posthoc test identified three distinct
homogeneous treatment subsets (A–C), showing significant incremental
differences in mutant (MT immunopositive) patch formation: (A) Groups
1–4, Distilled water, DMSO or lCgN only (1 and 4%); (B) Group 5, MNU
alone; (C) Groups 7 and 9, MNU and one or three 7 day cycles of 4%
lCgN. Groups 6, 8, 10 and 11 overlapped subsets B and C. (C) Large MT
immunopositive patch. An example of a large patch comprising 5 MT
immunopositive crypts, from a combined lCgN/MNU treatment group.
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Figure 2 Treatment effects on ACF. (A) Effects of treatment regimens
on ACF number in murine colon. One-way analysis of variance
demonstrated significant between-group differences in numbers of ACF
per 104 colonic crypts (Po0.001). The Duncan post hoc test identified 5
homogeneous treatment subsets (A–E), showing significant incremental
differences in frequency of ACF formation: (A) Groups 1–4, Distilled
water, DMSO or lCgN only (1 and 4%); (B) Group 5, MNU alone; (C)
Groups 6 and 7, MNU and one 7 day cycle of 1 or 4% lCgN; (D) Group 8,
MNU and three 7-day cycles of 1% lCgN; (E) Groups 9 and 11, MNU and
either three 7-day cycles of 4% lCgN or continuous 4% lCgN. These
subsets showed significant incremental differences of mean ACF per 104
colonic crypts. Group 10 (MNU and 3 7-day cycles of 4% lCgN)
overlapped subsets C and D. (B) Effects of treatment regimens on size
of ACF (crypt multiplicity). One-way analysis of variance demonstrated
significant between-group differences in numbers of aberrant crypts per
focus {crypt multiplicity} (Po0.01). The Duncan post hoc test identified 5
homogeneous treatment subsets (A–E), showing significant incremental
differences in crypt multiplicity: (A) groups 1 and 2, distilled water alone or
DMSO alone; (B) groups 3 and 4, continuous treatment with 1 or 4%
lCgN alone; (C) groups 5 and 6, MNU alone or MNU and 1 7-day cycle
of 1% lCgN; (D) groups 9 and 11, MNU and either 3 7-day cycles of 4%
lCgN or continuous 4% lCgN; (E) group 8, MNU and three 7-day cycles
of 1% lCgN. Groups 7 and 10 (MNU and 1 7-day cycle of 4% lCgN or
continuous 1% lCgN) overlapped subsets D and E.
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carcinoma. Since these events are stochastic, a higher stem
cell mutation rate may accelerate distinct stages of this
process (Herrero-Jimenez et al, 1998). Robust biomarkers of
stem cell mutation may thus provide useful surrogates of
tumorigenesis. Metallothionein crypt-restricted immuno-
positivity indices provide a stem cell mutation marker that is
initiated by mutagen exposures, yet mimics sporadic tumori-
genesis because it occurs in widely scattered single crypts or
foci throughout the otherwise normal colon (Cook et al, 2000).
Since the relationship of MT crypt-restricted immunopositivity
to tumorigenesis was unclear, we assessed the relationship
between MTCRII and ACF frequency, in mice treated by lCgN
and MNU.
The present study uses a similar combinatorial design, involving
a single MNU treatment (62.5 mg kg1) together with single,
repeated or continuous exposures to low- (1%) or high- (4%) dose
lCgN, to that of our previous study (Donnelly et al, 2004). In the
present study however, follow-up and continuous lCgN treatment
were continued for longer term (20 weeks). The present study
supports our earlier work and shows that lCgN alone does not
significantly affect MTCRII, but enhances MNU effects upon this
end point (Donnelly et al, 2004). However, sequential or prolonged
lCgN exposure to 20 weeks was associated with the development
of larger MT-immunopositive (mutant) patches than observed at
10 weeks, in our previous study.
Hence, prolonged lCgN exposure may have cumulative effects
upon mutant patch size. These effects could be related to lCgN-
induced tissue injury in mouse colon (Donnelly et al, 2004), fission
of immunopositive crypts and formation or enlargement of
immunopositive patches, during continual or repeated regenera-
tive healing.
While biomarkers of rate-limiting steps of tumorigenesis are
informative, validation against tumour-associated end points is
important. Aberrant crypt foci comprise a contiguous collection of
crypts that have thickened epithelia, altered luminal openings
and are clearly circumscribed from adjacent normal crypts
(Bird, 1987). Gene mutations that are commonly observed in
colon cancers including K-ras and APC are also observed in
a proportion of ACF (Pretlow et al, 1993; Smith et al, 1994).
Aberrant crypt foci are thus considered to represent early-
stage colorectal tumorigenesis (Bird, 1987; Tudek et al, 1989;
Takayama et al, 1998; Bird and Good, 2000), although large or
persistent ACF may have greater cancer risk (Papanikolaou et al,
2000). The present study has shown that MTCRII may reflect
combined effects of chemicals within a mixture, are induced in
sufficient numbers to provide statistical power from relatively
small animal samples and correlate with ACF formation at 20
weeks after the initiation of treatment. MTCRII may thus provide
the basis for an intermediate risk assessment model for diet- or
lifestyle-related genotoxic/nongenotoxic chemical combinations,
relevant to colonic health.
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Table 3 Treatment effects upon number and size of ACF
Group Treatment Mice (n) No. of ACF per colon No. of ACF per 104 crypts No. of aberrant crypts per ACF
1 Water only 5 0.4070.24 0.0970.04 0.6070.28
2 DMSO only 5 0.2070.20 0.0770.04 0.4070.25
3 Continuous 1% lCgN 5 0.8070.20 0.2170.04 1.6070.34
4 Continuous 4% lCgN 5 1.0070 0.2570.005 2.4070.24
5 MNU only 10 3.9070.23 1.3770.015 4.0070.17
6 MNU+1 7-day cycle 1% lCgN 10 5.0070.29 1.6770.18 4.0070.16
7 MNU+1 7-day cycle 4% lCgN 10 4.9070.23 1.5670.14 5.9070.21
8 MNU+3 7-day cycle 1% lCgN 10 5.8070.24 2.0470.14 6.5870.33
9 MNU+3 7-day cycle 4% lCgN 10 6.7070.21 2.5270.39 5.8070.17
10 MNU+continuous 1% lCgN 10 5.0070.25 1.6570.14 5.9070.22
11 MNU+continuous 4% lCgN 10 6.8070.29 2.9570.21 5.3870.26
ACF¼ aberrant crypt foci; DMSO¼ dimethylsulphoxide; lCgN¼ lambda carrageenan; MNU¼N-methyl-N-nitrosourea.
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Figure 3 Correlations between MTCRII and ACF. (A) Total MT-
immunopositive crypt number vs number of ACF per 104 crypts.
Correlation between total MT-immunopositive crypt number and ACF
per 104 crypts in all treatment groups (r¼ 0.732; Po0.01 by Pearson’s
product moment test). (B) Total MT-immunopositive crypt number vs size
of ACF. Correlation between total MT-immunopositive crypt number per
104 crypts and ACF size in all treatment groups (r¼ 0.84; Po0.01 by
Pearson’s product moment test).
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